Literature DB >> 21325837

Nasal drug delivery in humans.

Christoph Bitter, Katja Suter-Zimmermann, Christian Surber.   

Abstract

Intranasal administration is an attractive option for local and systemic delivery of many therapeutic agents. The nasal mucosa is--compared to other mucosae--easily accessible. Intranasal drug administration is noninvasive, essentially painless and particularly suited for children. Application can be performed easily by patients or by physicians in emergency settings. Intranasal drug delivery offers a rapid onset of therapeutic effects (local or systemic). Nasal application circumvents gastrointestinal degradation and hepatic first-pass metabolism of the drug. The drug, the vehicle and the application device form an undividable triad. Its selection is therefore essential for the successful development of effective nasal products. This paper discusses the feasibility and potential of intranasal administration. A series of questions regarding (a) the intended use (therapeutic considerations), (b) the drug, (c) the vehicle and (d) the application device (pharmaceutical considerations) are addressed with a view to their impact on the development of products for nasal application. Current and future trends and perspectives are discussed.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325837     DOI: 10.1159/000321044

Source DB:  PubMed          Journal:  Curr Probl Dermatol        ISSN: 1421-5721


  24 in total

Review 1.  Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.

Authors:  Thomas C Chen; Clovis O Da Fonseca; Axel H Schönthal
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 2.  Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals.

Authors:  Daniella Calderon-Nieva; Kalhari Bandara Goonewardene; Susantha Gomis; Marianna Foldvari
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

3.  Intranasal delivery of FSD-C10, a novel Rho kinase inhibitor, exhibits therapeutic potential in experimental autoimmune encephalomyelitis.

Authors:  Yan-Hua Li; Jie-Zhong Yu; Chun-Yun Liu; Hui Zhang; Hai-Fei Zhang; Wan-Fang Yang; Jun-Lian Li; Qian-Jin Feng; Ling Feng; Guang-Xian Zhang; Bao-Guo Xiao; Cun-Gen Ma
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

4.  Optimal Volume of Administration of Intranasal Midazolam in Children: A Randomized Clinical Trial.

Authors:  Daniel S Tsze; Maria Ieni; Daniel B Fenster; John Babineau; Joshua Kriger; Bruce Levin; Peter S Dayan
Journal:  Ann Emerg Med       Date:  2016-11-04       Impact factor: 5.721

5.  Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.

Authors:  James C League-Pascual; Cynthia M Lester-McCully; Shaefali Shandilya; Lukas Ronner; Louis Rodgers; Rafael Cruz; Cody J Peer; William D Figg; Katherine E Warren
Journal:  J Neurooncol       Date:  2017-03-13       Impact factor: 4.130

Review 6.  New Non-Intravenous Routes for Benzodiazepines in Epilepsy: A Clinician Perspective.

Authors:  Marco Mula
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

7.  Repurposing ibuprofen-loaded microemulsion for the management of Alzheimer's disease: evidence of potential intranasal brain targeting.

Authors:  Ming Ming Wen; Noha Ismail Khamis Ismail; Maha M A Nasra; Amal Hassan El-Kamel
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

8.  Phase 1 pharmacokinetics and phase 3 efficacy of testosterone nasal gel in subjects with seasonal allergies.

Authors:  Alan D Rogol; Natalia Tkachenko; Philipp Badorrek; Jens M Hohlfeld; Nathan Bryson
Journal:  Can Urol Assoc J       Date:  2018-03-19       Impact factor: 1.862

Review 9.  Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases.

Authors:  Thomas C Chen; Clovis O Da Fonseca; Axel H Schönthal
Journal:  Int J Mol Sci       Date:  2016-09-02       Impact factor: 5.923

Review 10.  Intranasal treatment of central nervous system dysfunction in humans.

Authors:  Colin D Chapman; William H Frey; Suzanne Craft; Lusine Danielyan; Manfred Hallschmid; Helgi B Schiöth; Christian Benedict
Journal:  Pharm Res       Date:  2012-11-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.